The growing popularity for muscle-building peptides has spawned a booming grey market, presenting both intriguing possibilities and considerable risks. These unlicensed products, often obtained from international suppliers, bypass traditional pharmaceutical processes, enabling access at discounted prices. However, the shortage of quality control an